Evonik Industries AG Adjusts 2026 Financial Outlook Upwards

Evonik Industries AG has announced revised financial expectations for the second quarter and full year of 2026. The company now anticipates an adjusted EBITDA between €600 million and €650 million for Q2 2026, exceeding last year's €509 million and current market projections of €567 million. This increase is attributed to higher sales volumes and prices, coupled with ongoing cost reductions. Evonik's Advanced Technologies segment is notably benefiting from supply chain disruptions affecting Asian competitors.

The favorable conditions may weaken as global marine shipping stabilizes post the reopening of the Strait of Hormuz. However, the Animal Nutrition segment is predicted to retain its positive trajectory into Q3. For the first half of 2026, adjusted EBITDA is projected to reach around €1.1 billion.

Consequently, Evonik has raised its full-year 2026 EBITDA outlook to a range between €2.0 billion and €2.2 billion, up from the previous €1.7 billion to €2.0 billion forecast. The 2025 adjusted EBITDA was approximately €1.9 billion. Additionally, the company maintains a free cash flow target with a 40% cash conversion rate, expecting significant improvement over the previous year's second quarter's negative free cash flow.